# Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

> **NCT05771896** · PHASE3 · WITHDRAWN · sponsor: **GenesisCare USA**

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Radium-223

## Key facts

- **NCT ID:** NCT05771896
- **Lead sponsor:** GenesisCare USA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2028-12
- **Final completion:** 2029-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Bayer withdrew their support.
- **Last updated:** 2023-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05771896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05771896, "Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05771896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*